CLOs on the Move

New Health Sciences

www.newhealthsciences.com

 
New Health Sciences is developing Hemanext, a technology designed to improve the safety and efficacy of transfusion therapy through novel storage methods.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Quotient Sciences

Quotient Sciences is a drug development and manufacturing accelerator supporting customers from candidate selection to commercial launch.

Cirrus Pharmaceuticals

Cirrus Pharmaceuticals is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ROSE LifeScience

Cultivation. Commercialization. Logistics. Yes, we`re here to make your life and work happier, and it starts with remarkable cannabis. It continues with business-ready services which help simplify the regulated world. From our proud home in Huntingdon, our family of marketers, growers and industry leaders at ROSE LifeScience are making cannabis thrive in Québec — for our customers, partners, communities and (especially) for you. Happiness is indeed our business. More importantly, it`s the reason why we do business.

KORU Medical

The home infusion industry turns to KORU Medical Systems to help patients and medical professionals improve infusion therapy experiences and we have a passion and vision for doing just that! We focus on home and specialty infusion solutions, emphasizing responsive problem-solving for our customers with careful consideration to the patient experience. The company was incorporated in March 1980 and is now publicly traded on the NASDAQ Capital Market (NASDAQ: KRMD). We are located in Chester, NY (USA), just 60 miles northwest of New York City. Our primary products include the FREEDOM60® and FreedomEdge® Syringe Infusion Systems, Precision Flow Rate Tubing™, and HIgH-Flo Subcutaneous Safety Needle Sets.

OrphoMed Inc

OrphoMed is a San Francisco based clinical stage pharmaceutical company focused on the development of novel first-in-class dimer conjugates with superior therapeutic profiles. The company is leveraging its proprietary dimer platform technology to address the issues of visceral hypersensitivity and hypermotility in functional gastrointestinal disorders. OrphoMed dimers are protected by composition of matter and method of use patents.